New cell sources for CAR-based immunotherapy

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazinani, Marzieh, Rahbarizadeh, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163725/
https://www.ncbi.nlm.nih.gov/pubmed/37147740
http://dx.doi.org/10.1186/s40364-023-00482-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163725/
https://www.ncbi.nlm.nih.gov/pubmed/37147740
http://dx.doi.org/10.1186/s40364-023-00482-9

Ejemplares similares